Skip to main content

Table 5 Univariate and multivariate logistic regression analyses of irAEs

From: Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis

 

Univariate analyses

Multivariate analyses

P value

OR

95% CI

P value

OR

95% CI

Sex

0.330

0.646

0.268–1.555

—

—

—

Age

0.975

1.001

0.957–1.046

—

—

—

ECOG

0.0499*

0.507

0.241–1.065

0.046*

0.159

0.026–0.970

 0–1 c

      

 2

      

Tumor type

0.795

1.018

0.892–1.161

0.770

—

—

TNM clinical classification

0.508

0.786

0.385–1.605

—

—

—

Treatment line

0.150

1.939

0.787–4.777

0.69

2.908

0.922–9.169

 First-line and second-line c

      

 Third-line and above

      

Treatment

0.125

0.780

0.567–1.072

0.044*

—

—

 Immunotherapy c

   

Base

—

—

 Immunotherapy + targeted therapy

   

0.005*

0.156

0.045–0.544

 Immunotherapy + chemotherapy

   

0.301

0.550

0.178–1.706

 Immunotherapy + chemotherapy + targeted therapy

   

0.383

0.363

0.037–3.533

NLR

0.0499*

0.196

0.038–1.000

0.505

0.501

0.066–3.816

 Low (≤ 8.58) c

      

 High (> 8.58)

      

PLR

0.091

0.492

0.216–1.120

0.216

0.537

0.200–1.440

 Low (< 180.68) c

      

 High (≥ 180.68)

      

AEC

0.012*

3.651

1.322–10.076

0.014*

4.114

1.32–12.858

 Low (≤ 0.045 × 109/L) c

      

 High (> 0.045 × 109/L)

      
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group, NLR Neutrophil-to-lymphocyte ratio, PLR Platelet-to-lymphocyte ratio, AEC Absolute eosinophil count, OR Odds ratio, CI Confidence interval
  2. *P < 0.05. cComparison reference in multivariate analyses